[1]
|
Bray, F., Ferlay, J., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[3]
|
董航, 刘华章, 林国桢, 等. 广州市2000-2011年宫颈癌发病趋势及年龄分布特征[J]. 中华疾病控制杂志, 2015, 19(5): 451-453, 480.
|
[4]
|
Tosic Golubovic, S., Binic, I., Krtinic, D., et al. (2022) Risk Factors and Predictive Value of Depression and Anxiety in Cervical Cancer Patients. Me-dicina, 58, Article 507. https://doi.org/10.3390/medicina58040507
|
[5]
|
周小燕, 苗格, 刘艺璇, 等. 延安市宫颈癌发病的生物危险因素的病例对照研究[J]. 现代肿瘤医学, 2023, 31(23): 4383-4387.
|
[6]
|
Li, X.Y., Li, G., Gong, T.T., et al. (2023) Non-Genetic Factors and Risk of Cervical Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. International Journal of Public Health, 68, Article ID: 1605198. https://doi.org/10.3389/ijph.2023.1605198
|
[7]
|
陈梦娟, 陈尧, 夏百荣, 等. 妇科恶性肿瘤术后绝经症状的激素治疗[J]. 安徽医学, 2023, 44(11): 1292-1294.
|
[8]
|
宫颈癌概述及误诊现状[J]. 临床误诊误治, 2021, 34(2): 2.
|
[9]
|
Zhao, F.J., Su, Q., Zhang, W., Yang, W.C., Zhao, L. and Gao, L.Y. (2021) Endu Combined with Concurrent Chemotherapy and Radiotherapy for Stage IIB-IVA Cervical Squamous Cell Carcinoma Patients. World Journal of Clin-ical Cases, 9, 8061-8070. https://doi.org/10.12998/wjcc.v9.i27.8061
|
[10]
|
Song, L., Liu, S., Zeng, S., Zhang, L. and Li, X. (2015) miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway. Medical Science Monitor, 21, 2210-2217.
https://doi.org/10.12659/MSM.893859
|
[11]
|
胡华斌, 邓艳红. 帕博利珠单抗在微卫星高度不稳定/错配修复缺陷的非结肠癌患者中的疗效: KEYNOTE-158II期研究的结果[J]. 中国肿瘤临床, 2023, 50(15): 774-777.
|
[12]
|
黄钊惠. 微卫星高度不稳定对胃癌术后辅助化疗疗效的影响[D]: [硕士学位论文]. 南昌: 南昌大学, 2021.
https://doi.org/10.27232/d.cnki.gnchu.2021.000861
|
[13]
|
Lu, L., Zhan, M., Li, X.Y., et al. (2022) Clinically Ap-proved Combination Immunotherapy: Current Status, Limitations, and Future Perspective. Current Research in Immu-nology, 3, 118-127. https://doi.org/10.1016/j.crimmu.2022.05.003
|
[14]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesoph-ageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[15]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Can-cer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[16]
|
Jain, R.K. (2005) Normalization of Tumor Vasculature: An Emerg-ing Concept in Antiangiogenic Therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
|
[17]
|
Pfister, C., Gravis, G., Fléchon, A., et al. (2021) Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxoru-bicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-Invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European Urology, 79, 214-221. https://doi.org/10.1016/j.eururo.2020.08.024
|
[18]
|
Chao, J., Fuchs, C.S., Shitara, K., et al. (2021) Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite In-stability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 7, 895-902. https://doi.org/10.1001/jamaoncol.2021.0275
|
[19]
|
Pfaendler, K.S. and Tewari, K.S. (2016) Changing Paradigms in the Systemic Treatment of Advanced Cervical Cancer. American Journal of Obstetrics & Gynecology, 214, 22-30. https://doi.org/10.1016/j.ajog.2015.07.022
|
[20]
|
Mauricio, D., Zeybek, B., Tymon-Rosario, J., Harold, J. and Santin, A.D. (2021) Immunotherapy in Cervical Cancer. Current Oncology Reports, 23, Article No. 61. https://doi.org/10.1007/s11912-021-01052-8
|
[21]
|
梁楠, 魏芳. 错配修复基因及其在妇科肿瘤中的研究进展[J]. 中华临床医师杂志(电子版), 2016, 10(6): 853-857.
|
[22]
|
Cohen, R., Hain, E., Buhard, O., et al. (2019) Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer with Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncology, 5, 551-555. https://doi.org/10.1001/jamaoncol.2018.4942
|
[23]
|
Yamamoto, H. and Imai, K. (2015) Microsatellite Instability: An Update. Archives of Toxicology, 89, 899-921.
https://doi.org/10.1007/s00204-015-1474-0
|
[24]
|
Lynch, H.T., Shaw, M.W., Magnuson, C.W., Larsen, A.L. and Krush, A.J. (1966) Hereditary Factors in Cancer. Study of Two Large Midwestern Kindreds. Archives of Internal Medi-cine, 117, 206-212.
https://doi.org/10.1001/archinte.1966.03870080050009
|
[25]
|
Wendel Naumann, R. and Leath III, C.A. (2020) Ad-vances in Immunotherapy for Cervical Cancer. Current Opinion in Oncology, 32, 481-487. https://doi.org/10.1097/CCO.0000000000000663
|
[26]
|
Qi, J., Sun, H., Zhang, Y., et al. (2022) Single-Cell and Spatial Analysis Reveal Interaction of FAP+ Fibroblasts and SPP1+ Macrophages in Colorectal Cancer. Nature Com-munications, 13, Article No. 1742.
https://doi.org/10.1038/s41467-022-29366-6
|
[27]
|
孙焕欣. PD-L1、PD-1与MMR蛋白在胃癌中的表达及临床意义的研究[D]: [硕士学位论文]. 南充: 川北医学院, 2020. https://doi.org/10.27755/d.cnki.gcbyx.2020.000197
|
[28]
|
Baretti, M. and Le, D.T. (2018) DNA Mismatch Repair in Cancer. Pharmacology & Therapeutics, 189, 45-62.
https://doi.org/10.1016/j.pharmthera.2018.04.004
|
[29]
|
田文芳, 唐洁. 帕博利珠单抗在微卫星高度不稳定的晚期子宫内膜癌患者中的疗效和安全性: 来自KEYNOTE-158研究的结果[J]. 中国肿瘤临床, 2023, 50(15): 764-768.
|
[30]
|
纪晓宇. 宫颈神经内分泌癌的预后分析及其PD-L1、PARP1表达与治疗意义[D]: [硕士学位论文]. 青岛: 青岛大学, 2022.
|
[31]
|
Kelderman, S., Schumacher, T.N. and Kvistborg, P. (2015) Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. Cancer Cell, 28, 11-13. https://doi.org/10.1016/j.ccell.2015.06.012
|
[32]
|
宁臣功, 孙岩波, 孙锋. 免疫检查点抑制剂联合治疗在微卫星稳定型结直肠癌治疗中的研究进展[J]. 肿瘤代谢与营养电子杂志, 2023, 10(2): 277-282. https://doi.org/10.16689/j.cnki.cn11-9349/r.2023.02.019
|
[33]
|
McGrail, D.J., Pilié, P.G., Rashid, N.U., et al. (2021) High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across All Cancer Types. Annals of Oncology, 32, 661-672.
https://doi.org/10.1016/j.annonc.2021.02.006
|
[34]
|
Seifert, M. and Reichrath, J. (2006) The Role of the Human DNA Mismatch Repair Gene hMSH2 in DNA Repair, Cell Cycle Control and Apoptosis: Implications for Pathogenesis, Progression and Therapy of Cancer. Journal of Molecular Histology, 37, 301-307. https://doi.org/10.1007/s10735-006-9062-5
|
[35]
|
王靖, 宋晓燕. 宫颈癌染色体杂和性缺失与微卫星不稳定性[J]. 内蒙古医学杂志, 2010, 42(S5): 50-52.
https://doi.org/10.16096/j.cnki.nmgyxzz.2010.s5.126
|
[36]
|
Kumar, L. and Gupta, S. (2016) Integrating Chemo-therapy in the Management of Cervical Cancer: A Critical Appraisal. Oncology, 91, 8-17. https://doi.org/10.1159/000447576
|
[37]
|
Buskwofie, A., David-West, G. and Clare, C.A. (2020) A Review of Cer-vical Cancer: Incidence and Disparities. Journal of the National Medical Association, 112, 229-232. https://doi.org/10.1016/j.jnma.2020.03.002
|
[38]
|
张彦, 王琳, 张梅. Musashi-2在宫颈癌中高表达并促进宫颈癌细胞恶性生物学行为[J]. 中国妇幼保健, 2019, 34(4): 918-921.
|